StreetInsider.com News Articles

Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Mon, 01 Jun 2026 17:00:00 -0400

SAN DIEGO, June 01, 2026 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical oncology innovator advancing late-stage development of investigational first-in-class WEE1 inhibitor azenosertib as a biomarker-driven treatment approach for ovarian cancer, today announced that on June 1, 2026, the Compensation Committee of Zentalis’ Board of Directors granted non-qualified stock options to purchase an aggregate of 191,000 shares of the Company’s common stock to two (2) newly hired employees. The stock options were granted under the Zentalis Pharmaceuticals, Inc. 2022 Employment Inducement Incentive Award Plan (2022 Inducement Plan) as an inducement material to each such individual’s

Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Mon, 01 Jun 2026 17:00:00 -0400

Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Mon, 01 Jun 2026 17:00:00 -0400

Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Mon, 01 Jun 2026 17:00:00 -0400

Form 4 Zentalis Pharmaceuticals For: May 26 Filed by: Campbell Shannon

Wed, 27 May 2026 16:11:00 -0400

si-local-file:///var/storage/secattach/20260527/26557962.html

Form 4 Zentalis Pharmaceuticals For: May 26 Filed by: Campbell Shannon

Wed, 27 May 2026 16:11:00 -0400

si-local-file:///var/storage/secattach/20260527/26557962.html

Form 3 Zentalis Pharmaceuticals For: May 22 Filed by: Campbell Shannon

Wed, 27 May 2026 16:10:00 -0400

si-local-file:///var/storage/secattach/20260527/26557942.html

Form 3 Zentalis Pharmaceuticals For: May 22 Filed by: Campbell Shannon

Wed, 27 May 2026 16:10:00 -0400

si-local-file:///var/storage/secattach/20260527/26557942.html

Form DEFA14A Zentalis Pharmaceuticals

Wed, 27 May 2026 16:08:00 -0400

si-local-file:///var/storage/secattach/20260527/26557883.html

Form DEFA14A Zentalis Pharmaceuticals

Wed, 27 May 2026 16:08:00 -0400

si-local-file:///var/storage/secattach/20260527/26557883.html

Form 8-K Zentalis Pharmaceuticals For: May 22

Wed, 27 May 2026 16:07:00 -0400

si-local-file:///var/storage/secattach/20260527/26557859.html

Form 8-K Zentalis Pharmaceuticals For: May 22

Wed, 27 May 2026 16:07:00 -0400

si-local-file:///var/storage/secattach/20260527/26557859.html

Zentalis appoints Shannon Campbell to board, Sarah Kelly as commercial SVP

Wed, 27 May 2026 16:05:33 -0400

Zentalis Pharmaceuticals (NASDAQ: ZNTL) announced the appointment of Shannon Campbell to its board of directors and Sarah Kelly as senior vice president of commercial strategy. The appointments support the company's preparation for potential commercialization of its investigational drug azenosertib for ovarian cancer treatment.

Campbell brings over 30 years of biopharmaceutical experience, most recently serving as executive vice president and chief commercial officer at Merus. She previously held senior oncology leadership roles at Novartis Pharmaceuticals and Bayer Healthcare Pharmaceuticals. Campbell currently serves on the board of Black Diamond Therapeutics.